Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
30
KMTS Quote, Financials, Valuation and Earnings
Last price:
$24.54
Seasonality move
:
--
Day range:
$24.33 - $26.03
52-week range:
$13.25 - $30.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.98x
P/B ratio:
6.68x
Volume:
2.4M
Avg. volume:
315.1K
1-year change:
--
Market cap:
$1.2B
Revenue:
$59.8M
EPS (TTM):
-$2.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
$21M | -$0.57 | 47.27% | -19.87% | $27.86 |
|
AZTA
Azenta, Inc.
|
$156.4M | $0.20 | -0.42% | 86.12% | $39.83 |
|
BNGO
Bionano Genomics, Inc.
|
$6.9M | -$2.34 | -2.86% | -82.39% | $7.50 |
|
BRKR
Bruker Corp.
|
$847M | $0.33 | -2.12% | 622.18% | $48.83 |
|
HBIO
Harvard Bioscience, Inc.
|
$20M | $0.01 | -5.93% | 8650% | $2.00 |
|
PAHC
Phibro Animal Health Corp.
|
$345.4M | $0.60 | 15% | 756.68% | $43.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
$25.82 | $27.86 | $1.2B | -- | $0.00 | 0% | 14.98x |
|
AZTA
Azenta, Inc.
|
$35.60 | $39.83 | $1.6B | -- | $0.00 | 0% | 2.74x |
|
BNGO
Bionano Genomics, Inc.
|
$1.73 | $7.50 | $17.6M | -- | $0.00 | 0% | 0.20x |
|
BRKR
Bruker Corp.
|
$47.86 | $48.83 | $7.3B | 77.08x | $0.05 | 0.42% | 2.11x |
|
HBIO
Harvard Bioscience, Inc.
|
$0.73 | $2.00 | $32.4M | -- | $0.00 | 0% | 0.37x |
|
PAHC
Phibro Animal Health Corp.
|
$41.39 | $43.00 | $1.7B | 24.88x | $0.12 | 1.16% | 1.21x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
19.49% | 0.000 | 5.67% | 6.52x |
|
AZTA
Azenta, Inc.
|
2.89% | 2.112 | 3.89% | 2.04x |
|
BNGO
Bionano Genomics, Inc.
|
25.67% | -1.308 | 103.34% | 1.58x |
|
BRKR
Bruker Corp.
|
45.23% | 0.852 | 40.19% | 0.76x |
|
HBIO
Harvard Bioscience, Inc.
|
75.26% | 4.098 | 218.87% | 0.35x |
|
PAHC
Phibro Animal Health Corp.
|
71.58% | 2.736 | 47.87% | 1.12x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies Ltd.
|
$8.9M | -$28.9M | -74.84% | -104.63% | -149.08% | -$34.5M |
|
AZTA
Azenta, Inc.
|
$72.3M | $2.3M | 1.35% | 1.39% | 1.45% | -$5.7M |
|
BNGO
Bionano Genomics, Inc.
|
$3.4M | -$8.5M | -58.02% | -84.77% | -115.9% | -$5.9M |
|
BRKR
Bruker Corp.
|
$399.6M | $55.2M | -0.56% | -1.2% | 6.42% | -$54.1M |
|
HBIO
Harvard Bioscience, Inc.
|
$11.2M | $245K | -68.29% | -155.33% | 1.19% | $482K |
|
PAHC
Phibro Animal Health Corp.
|
$119.3M | $47.9M | 6.8% | 24.77% | 13.16% | -$4.5M |
Kestra Medical Technologies Ltd. vs. Competitors
-
Which has Higher Returns KMTS or AZTA?
Azenta, Inc. has a net margin of -133.32% compared to Kestra Medical Technologies Ltd.'s net margin of 31.94%. Kestra Medical Technologies Ltd.'s return on equity of -104.63% beat Azenta, Inc.'s return on equity of 1.39%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.45.69% -$0.50 $228.7M AZTAAzenta, Inc.45.4% $1.02 $1.8B -
What do Analysts Say About KMTS or AZTA?
Kestra Medical Technologies Ltd. has a consensus price target of $27.86, signalling upside risk potential of 7.89%. On the other hand Azenta, Inc. has an analysts' consensus of $39.83 which suggests that it could grow by 11.89%. Given that Azenta, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Azenta, Inc. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 AZTAAzenta, Inc.1 4 0 -
Is KMTS or AZTA More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Azenta, Inc. has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.831%.
-
Which is a Better Dividend Stock KMTS or AZTA?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Azenta, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or AZTA?
Kestra Medical Technologies Ltd. quarterly revenues are $19.4M, which are smaller than Azenta, Inc. quarterly revenues of $159.2M. Kestra Medical Technologies Ltd.'s net income of -$25.8M is lower than Azenta, Inc.'s net income of $50.9M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Azenta, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 14.98x versus 2.74x for Azenta, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.14.98x -- $19.4M -$25.8M AZTAAzenta, Inc.2.74x -- $159.2M $50.9M
-
Which has Higher Returns KMTS or BNGO?
Bionano Genomics, Inc. has a net margin of -133.32% compared to Kestra Medical Technologies Ltd.'s net margin of -115.42%. Kestra Medical Technologies Ltd.'s return on equity of -104.63% beat Bionano Genomics, Inc.'s return on equity of -84.77%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.45.69% -$0.50 $228.7M BNGOBionano Genomics, Inc.45.75% -$1.59 $67M -
What do Analysts Say About KMTS or BNGO?
Kestra Medical Technologies Ltd. has a consensus price target of $27.86, signalling upside risk potential of 7.89%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 333.53%. Given that Bionano Genomics, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Bionano Genomics, Inc. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 BNGOBionano Genomics, Inc.1 0 0 -
Is KMTS or BNGO More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 2.336, suggesting its more volatile than the S&P 500 by 133.592%.
-
Which is a Better Dividend Stock KMTS or BNGO?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or BNGO?
Kestra Medical Technologies Ltd. quarterly revenues are $19.4M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Kestra Medical Technologies Ltd.'s net income of -$25.8M is lower than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 14.98x versus 0.20x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.14.98x -- $19.4M -$25.8M BNGOBionano Genomics, Inc.0.20x -- $7.4M -$8.5M
-
Which has Higher Returns KMTS or BRKR?
Bruker Corp. has a net margin of -133.32% compared to Kestra Medical Technologies Ltd.'s net margin of -6.8%. Kestra Medical Technologies Ltd.'s return on equity of -104.63% beat Bruker Corp.'s return on equity of -1.2%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.45.69% -$0.50 $228.7M BRKRBruker Corp.46.44% -$0.41 $4.5B -
What do Analysts Say About KMTS or BRKR?
Kestra Medical Technologies Ltd. has a consensus price target of $27.86, signalling upside risk potential of 7.89%. On the other hand Bruker Corp. has an analysts' consensus of $48.83 which suggests that it could grow by 2.03%. Given that Kestra Medical Technologies Ltd. has higher upside potential than Bruker Corp., analysts believe Kestra Medical Technologies Ltd. is more attractive than Bruker Corp..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 BRKRBruker Corp.5 6 0 -
Is KMTS or BRKR More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.405%.
-
Which is a Better Dividend Stock KMTS or BRKR?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.42% to investors and pays a quarterly dividend of $0.05 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or BRKR?
Kestra Medical Technologies Ltd. quarterly revenues are $19.4M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Kestra Medical Technologies Ltd.'s net income of -$25.8M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 14.98x versus 2.11x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.14.98x -- $19.4M -$25.8M BRKRBruker Corp.2.11x 77.08x $860.5M -$58.5M
-
Which has Higher Returns KMTS or HBIO?
Harvard Bioscience, Inc. has a net margin of -133.32% compared to Kestra Medical Technologies Ltd.'s net margin of -5.98%. Kestra Medical Technologies Ltd.'s return on equity of -104.63% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.45.69% -$0.50 $228.7M HBIOHarvard Bioscience, Inc.54.23% -$0.03 $56.9M -
What do Analysts Say About KMTS or HBIO?
Kestra Medical Technologies Ltd. has a consensus price target of $27.86, signalling upside risk potential of 7.89%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 174.88%. Given that Harvard Bioscience, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Harvard Bioscience, Inc. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 HBIOHarvard Bioscience, Inc.1 1 0 -
Is KMTS or HBIO More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.123%.
-
Which is a Better Dividend Stock KMTS or HBIO?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or HBIO?
Kestra Medical Technologies Ltd. quarterly revenues are $19.4M, which are smaller than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Kestra Medical Technologies Ltd.'s net income of -$25.8M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 14.98x versus 0.37x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.14.98x -- $19.4M -$25.8M HBIOHarvard Bioscience, Inc.0.37x -- $20.6M -$1.2M
-
Which has Higher Returns KMTS or PAHC?
Phibro Animal Health Corp. has a net margin of -133.32% compared to Kestra Medical Technologies Ltd.'s net margin of 7.29%. Kestra Medical Technologies Ltd.'s return on equity of -104.63% beat Phibro Animal Health Corp.'s return on equity of 24.77%.
Company Gross Margin Earnings Per Share Invested Capital KMTSKestra Medical Technologies Ltd.45.69% -$0.50 $228.7M PAHCPhibro Animal Health Corp.32.8% $0.65 $1.1B -
What do Analysts Say About KMTS or PAHC?
Kestra Medical Technologies Ltd. has a consensus price target of $27.86, signalling upside risk potential of 7.89%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 3.89%. Given that Kestra Medical Technologies Ltd. has higher upside potential than Phibro Animal Health Corp., analysts believe Kestra Medical Technologies Ltd. is more attractive than Phibro Animal Health Corp..
Company Buy Ratings Hold Ratings Sell Ratings KMTSKestra Medical Technologies Ltd.5 1 0 PAHCPhibro Animal Health Corp.0 2 0 -
Is KMTS or PAHC More Risky?
Kestra Medical Technologies Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.
-
Which is a Better Dividend Stock KMTS or PAHC?
Kestra Medical Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.16% to investors and pays a quarterly dividend of $0.12 per share. Kestra Medical Technologies Ltd. pays 1.45% of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KMTS or PAHC?
Kestra Medical Technologies Ltd. quarterly revenues are $19.4M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Kestra Medical Technologies Ltd.'s net income of -$25.8M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Kestra Medical Technologies Ltd.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kestra Medical Technologies Ltd. is 14.98x versus 1.21x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KMTSKestra Medical Technologies Ltd.14.98x -- $19.4M -$25.8M PAHCPhibro Animal Health Corp.1.21x 24.88x $363.9M $26.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
